 Chemical structure of foscarbidopa | |
 Chemical structure of foslevodopa | |
| Combination of | |
|---|---|
| Foscarbidopa | Aromatic amino acid decarboxylation inhibitor |
| Foslevodopa | Aromatic amino acid |
| Clinical data | |
| Trade names | Vyalev, others |
| Other names | ABBV-951 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Foscarbidopa/foslevodopa, sold under the brand name Vyalev among others, is a fixed-dose combination medication used for the treatment of Parkinson's disease. [2] [5] It is a fixed-dose combination of foscarbidopa, an aromatic amino acid decarboxylation inhibitor and prodrug for carbidopa; [5] and foslevodopa, an aromatic amino acid and prodrug for levodopa that was developed by AbbVie. [5] [6] [7] [8] [9] [10] Its structure is identical to carbidopa/levodopa except for the replacement of a hydroxyl on each molecule with a phosphate group, similar to the antiepileptic prodrug fosphenytoin as it relates to phenytoin.[ citation needed ]
Contents
The combination was refused approval by the US Food and Drug Administration (FDA) in 2023. [11] It was approved for medical use in Canada in May 2023, [4] in Australia in March 2024, [1] and in the United States in October 2024. [12] [13]
Produodopa uses a pump to steadily release foscarbidopa/foslevodopa into the bloodstream round-the-clock. It is available via the UK National Health Service since February 2024. [14] [15]
